1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

US12319671B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Hua Zhou · Acton, US
• John J. Acton, III · Cranford, US
• Michael J. Ardolino · Arlington, US
• Yi-Heng Chen · Whippany, US
• Peter H. Fuller · Ashland, US
• Anmol Gulati · Watertown, US
• Rebecca Elizabeth Johnson · Arlington, US
• William P. Kaplan · Boston, US
• Solomon D. Kattar · Arlington, US
• Mitchell H. Keylor · Malden, US
• Derun Li · Dedham, US
• Kaitlyn Marie Logan · Boston, US
• Min Lu · San Diego, US
• Gregori J. Morriello · Dover, US
• Santhosh F. Neelamkavil · Edison, US
• Barbara Pio · West Orange, US
• Nunzio Sciammetta · Sudbury, US
• Vladimir Simov · Boston, US
• Jing Su · Scotch Plains, US
• Luis Torres · Norwood, US
• Xin Yan · Newton, US

Key dates

• Filing date: Jun 1, 2020
• Grant date: Jun 3, 2025
• Expiry date: Aug 29, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.